Harwood Feffer LLP is investigating potential claims against CytRx Corporation (NASDAQ:CYTR) concerning whether it has violated the federal securities laws. On March 13, 2014, a media report stated that the Company had hired an entity to promote CytRx stock that published a number of articles on the internet without disclosing that the Company had paid for the positive reporting. At the same time, CytRx insiders were selling $86 million of new equity to investors. CytRx Corporation (NASDAQ:CYTR) shares after opening at $3.81 on last trade day and at the end of the day closed at $4.15. Company price to sales ratio in past twelve months was calculated as 557.28 and price to cash ratio as 4.33. CytRx Corporation (NASDAQ:CYTR) showed a negative weekly performance of -21.99%.
TheStreet Quant Ratings rates OXiGENE Inc (NASDAQ:OXGN) as a sell. The company’s weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, disappointing return on equity and generally disappointing historical performance in the stock itself. OXiGENE Inc (NASDAQ:OXGN) shares fell -4.55% in last trading session and ended the day on $3.99. OXGN return on equity ratio is recorded as -212.60% and its return on assets is -180.80%. OXiGENE Inc (NASDAQ:OXGN) yearly performance is -0.25%.
Coronado Biosciences, Inc. (NASDAQ:CNDO) announced its financial results for the fourth quarter and year ended December 31, 2013. “Given the results of our TRUST-I Clinical Trial for Crohn’s Disease, we are evaluating clinical development plans for TSO,” said Dr. Lindsay A. Rosenwald, Coronado’s Chairman, President and CEO. “As part of our growth strategy, we plan to identify, evaluate and potentially in-license, acquire or invest in pharmaceutical and biotechnology products, technologies and/or companies. We may also from time to time consider financing existing or later-acquired products, technologies or companies through partnerships, joint ventures, direct financings, and/or public or private spin-outs. We believe these activities will diversify our product development and, over time, may enhance shareholder value
through potential royalty, milestone and equity payments, fees as well as potential product revenues.” Coronado Biosciences Inc (NASDAQ:CNDO) weekly performance is -14.07%. On last trading day company shares ended up $2.26. Coronado Biosciences Inc (NASDAQ:CNDO) distance from 50-day simple moving average (SMA50) is -17.03%. Analysts mean target price for the company is $1.90.
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Galena Biopharma Inc (NASDAQ:GALE) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of Oregon. The complaint alleges that the company and certain of its officers and directors violated the Securities and Exchange Act of 1934 between November 6, 2013 and February 14, 2014 (the “Class Period”). Galena is a biopharmaceutical company focusing on the development of oncology treatments. Galena Biopharma Inc (NASDAQ:GALE) shares moved up 3.97% in last trading session and was closed at $3.14, while trading in range of $2.90 – $3.17. Galena Biopharma Inc (NASDAQ:GALE) year to date (YTD) performance is -36.69%.